PEOPLE - Management changes at Gynecare (US):
This article was originally published in Clinica
Executive Summary
William Hunter has recently resigned as president & CEO of Gynecare (US). These positions are being temporarily filled by Dr Lad Burgin, until a long-term replacement is found. Dr Burgin has worked closely with Gynecare in his capacity as president & CEO of the consulting firm, HRMG.
You may also be interested in...
Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire
Clarke helped launch GDUFA I and negotiate GDUFA II, chaired the CDER Executive Committee and oversaw many other programs in the US FDA’s drugs center.
Rx Advertising: Interchangeability Doesn’t Mean Clinical Superiority To Other Biosimilars, FDA Says
Updated draft guidance on promotion of biologic reference products, biosimilars and interchangeable biosimilars offers another indication of the US’s push to do away with the interchangeability designation.
Small Sterilization Companies Poised To Meet EtO Emissions Goals On Time
Small sterilizers told Medtech Insight that they were ready for the EPA’s controversial EtO emissions rule, while community advocates expressed concerns.